Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00768378 · ClinicalTrials.gov registry record · NA

Safety and Efficacy Study of BrainPort® Balance Device in Peripheral Vestibular Dysfunction.

A NA study, sponsored by Wicab.

Completed
Registry status
NA
Development phase
147
Enrollment target

NCT00768378: Completed NA study, sponsored by Wicab.

NCT00768378 is a NA study that has completed, run by Wicab. The registered enrollment target is 147 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00768378, a NA study, has completed, sponsored by Wicab.

COMPLETED
Registry status
NA
Development phase
147 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and efficacy of the BrainPort balance device in improving balance and gait as measured by clinically accepted standardized balance assessments in subjects with peripheral vestibular dysfunction.

Interventions

  • DEVICE Training with the BrainPort balance device

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2008-07
Est. Completion 2010-03
Phase NA
Wicab

4 total trials

What the finished NCT00768378 record still lists

NCT00768378 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which Training with the BrainPort balance device is the first listed.

NCT00768378 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00768378 about?

NCT00768378 is a clinical study titled "Safety and Efficacy Study of BrainPort® Balance Device in Peripheral Vestibular Dysfunction.". The purpose of this study is to assess the safety and efficacy of the BrainPort balance device in improving balance and gait as measured by clinically accepted standardized balance assessments in subjects with peripheral vestibular dysfunction.

What is the current status of trial NCT00768378?

This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2008-07. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00768378?

The interventions under investigation include: Training with the BrainPort balance device (DEVICE).

Who is sponsoring clinical trial NCT00768378?

This trial is sponsored by Wicab, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00768378's enrollment target sits among peer trials

147 703rd of 2000 higher than 1,297 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04396613 · 147 participants · NA

    Wound Closure Techniques in Primary Spine Surgery

  • NCT04851119 · 147 participants · Phase 1

    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NCT05523947 · 147 participants · Phase 1

    Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  • NCT06121843 · 147 participants · Phase 1

    A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00768378, the US trial registry maintained by the National Library of Medicine. NCT00768378 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.